Soleno治疗学公司新的Prader-Willi综合症药物获得了林业发展局的批准,增加了其库存量。 Soleno Therapeutics' new Prader-Willi syndrome drug gains FDA approval, boosting its stock.

索莱诺治疗 (SLNO) 最近获得FDA对VYKAT XR的批准,用于治疗普拉德-威利综合征,并且是2025年第三大表现最好的医疗保健股,年终日效率为70.81%. Soleno Therapeutics (SLNO) recently received FDA approval for VYKAT XR, treating Prader-Willi syndrome, and is the third-best-performing healthcare stock in 2025 with a YTD performance of 70.81%. 该公司还提供名为 " Soleno One " 的支助方案,以协助获得药物。 The company also offers a support program called Soleno ONE to assist with drug access. 来自H. C. Wainwright的Ram Selvaraju分析师在股票上维持了买入评级。 Analyst Ram Selvaraju from H.C. Wainwright maintains a Buy rating on the stock.